The Effect of Vedolizumab on Spondyloarthritis Symptoms in a Cohort of Inflammatory Bowel Disease Patients

OBJECTIVE: Vedolizumab is a novel anti-inflammatory molecule that is currently being used in the treatment of refractory inflammatory bowel disease. The mode of action is inhibiting the binding of activated T lymphocytes to the adhesion molecule 1 of intestinal mucosal cells. Due to its local effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Huseynzada, Sinakhanım, Yüce İnel, Tuba, Hajiyev, Farid, Köken Avşar, Aydan, Balcı, Ali, Akpınar, Hale, Önen, Fatoş, Sarı, İsmail
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mesut Onat 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542484/
https://www.ncbi.nlm.nih.gov/pubmed/37171478
http://dx.doi.org/10.5152/eurjrheum.2023.22049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542484/
https://www.ncbi.nlm.nih.gov/pubmed/37171478
http://dx.doi.org/10.5152/eurjrheum.2023.22049

Ejemplares similares